Opinion

Video

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

TAS-102 combination with bevacizumab are highlighted in the 3L setting for colorectal cancer.

Video Player is loading.
Current Time 0:00
Duration 6:11
Loaded: 0%
Stream Type LIVE
Remaining Time 6:11
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Content